Spots Global Cancer Trial Database for therasphere
Every month we try and update this database with for therasphere cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT02072356 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | yttrium Y 90 gl... laboratory biom... TheraSphere | 8 Years - | Ohio State University Comprehensive Cancer Center | |
| A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma | NCT01076517 | Liver Cancer | Therasphere | - | Stanford University | |
| TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer | NCT04090645 | Liver, Cancer o... | TheraSphere | 18 Years - | Methodist Health System | |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | NCT01864070 | Liver Cancer | TheraSphere Everolimus Phone Call | 18 Years - | M.D. Anderson Cancer Center | |
| First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device | NCT06192758 | Prostate Cancer | TheraSphere PCa | 50 Years - | Boston Scientific Corporation | |
| First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device | NCT06192758 | Prostate Cancer | TheraSphere PCa | 50 Years - | Boston Scientific Corporation | |
| Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | NCT03203837 | Hepatocellular ... | Plasma collecti... | 18 Years - | Northwestern University | |
| TheraSphere for the Treatment of Liver Metastases | NCT00511862 | Colorectal Canc... Carcinoma, Neur... Neoplasm Metast... | Yttrium 90 glas... | 18 Years - | Boston Scientific Corporation | |
| Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer | NCT01483027 | Colorectal Canc... | TheraSphere | 18 Years - | Boston Scientific Corporation | |
| A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC | NCT03295006 | Hepatocellular ... | TheraSphere | 18 Years - | Boston Scientific Corporation | |
| TheraSphere for the Treatment of Liver Metastases | NCT00511862 | Colorectal Canc... Carcinoma, Neur... Neoplasm Metast... | Yttrium 90 glas... | 18 Years - | Boston Scientific Corporation | |
| TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma | NCT01349075 | Hepatocellular ... | TheraSphere | 18 Years - | Thomas Jefferson University | |
| TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis | NCT01556282 | Liver Cancer Portal Vein Thr... | TheraSphere | 18 Years - | Emory University | |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | NCT01864070 | Liver Cancer | TheraSphere Everolimus Phone Call | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer | NCT01483027 | Colorectal Canc... | TheraSphere | 18 Years - | Boston Scientific Corporation | |
| Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | NCT00493883 | Carcinoma, Hepa... Liver Neoplasms | yttrium Y 90 mi... | 18 Years - | Southwestern Regional Medical Center | |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | NCT04659382 | Metastatic Colo... pMMR MSS Immune Checkpoi... Internal Radiot... | Atezolizumab Therasphere XELOX Bevacizumab | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | NCT03203837 | Hepatocellular ... | Plasma collecti... | 18 Years - | Northwestern University | |
| A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC | NCT03295006 | Hepatocellular ... | TheraSphere | 18 Years - | Boston Scientific Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
